ClinicalTrials.gg
RecruitingNCT07634718ITINERANCEUpdated Nov 13, 2026

Implementation Trial In patieNts With rEnal failuRe and diAbetes for Major Adverse reNal and Cardiovascular Events

An interventional study of Health-related messages in Diabetes and Renal Failure , Chronic, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 13, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.

Planned enrollment
Largest of 242
125,000 · median 187
Started
2026
with 10 others
No phase
100 of 352
22 open now
Primary completion
2029-07
later than 45 of 51 live
Registered
349th of 352
by date

Among the 352 studies in Diabetes Mellitus with a site in France, this one has the largest planned enrollment of the 242 interventional ones that give a count, is one of 11 that started in 2026, is one of 100 with no phase, reaches primary completion later than 45 of the 51 other live ones, and was the 349th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 352 studies in Diabetes Mellitus with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical study is to establish if the use of public health-related messages, designed and disseminated to a targeted population, will result in tangible improvements in patient outcomes and healthcare practices.

Specific health-related messages oriented towards patients, through their biological results and HealthCare Professionals (HCPs), will be sent to participants included in the intervention group. The control group will not receive any health-related message (routine care).

The aim is to evaluate if this intervention leads to differences in Major Adverse Renal and Cardiovascular Events (MARCE), compared to routine care (no dissemination of health messages) in patients suffering in diabetes and renal failure.

03

Conditions studied

  • Diabetes
  • Renal Failure , Chronic

Keywords

  • implementation
  • heatlh-related message
  • Renal and cardiovascular event
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Subject attending a ML participating to the study
  • Subject presenting a ≥ 6.5% and an estimated (CKD-EPI formula) in the range 60 to 15 ml/min (included) and/or albumin to creatinine ratio ≥ 300 mg albumin/g creatinine (or 30 mg/mmol creatinine), on the same biological determination.

Main exclusion criteria:

  • Subject previously identified as opposed to the use of their medical data and/or access of their SNDS data,
  • Subject not registered to the French social security system,
  • Subject with estimated GFR \< 15 ml/min on the day of inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
125,000 participants (estimated)

Study arms

  • Experimental
    health-related arm

    Participants will receive an health-related message included in the biological results form. A short graphical illustration will indicate the patient-risk level according the biological results and video detailing national recommendations. HCPs will receive a SIGNAL BIO message which was elaborated on evidence-based treatments and/or strategy for patients with diabetes.

    Other: Health-related messages

  • No intervention
    Control group

    Participants will get as in the routine care, no message will be disseminated for this group.

Interventions

  • OtherHealth-related messages

    Patient will be included in the intervention according to the laboratory's randomization arm.The intervention consists in delivering patient information messages in laboratory reports, providing access to an educational video for patients and a specific message for the prescribing physician in the intervention arm, without modifying patient care.

06

What researchers measure

Primary outcomes

  1. Major Adverse Renal and Cardiovascular Events (MARCE) occurrence

    Change in Major Adverse Renal and Cardiovascular Events (MARCE) occurrence defined as a composite outcome including the following items (first occurring): * All-cause death * Myocardial infarction (universal definition) * Stroke (universal definition) * Sustained (over 45 days) use of renal replacement therapy * Heart failure leading to hospitalization (definition by the European Society of Cardiology)

    Time frame: 2 years after randomization and dissemination of health-related messages

Secondary outcomes

  1. Specific health outcomes

    Change in specific health outcomes (separately analysed): * All-cause death * Myocardial infarction * Stroke * Sustained (over 1 month) use of renal replacement therapy * Heart failure leading to hospitalization * Lower limb amputation, with special information on the site of amputation (toe, transmetatarsal, transtibial, transfemoral) * Arterial revascularization in the coronary, cerebrovascular and/or lower aorta/lower limb territories * Severe diabetic retinopathy (laser procedure, eye surgery for diabetes complication and intravitreal injection associated with specific drug delivery and/or their combinations

    Time frame: 2 years after the randomization and dissemination of health-related messages

  2. Reimbursement claims of medications of special interest and visits to general practitioners and to specialists in cardiology, nephrology and diabetology

    Change in Reimbursement claims of medications of special interest and visits to general practitioners and to specialists in cardiology, nephrology and diabetology

    Time frame: 6 months and 2 years after randomization and dissemination of health-related messages

  3. Biological characteristics

    Changes in biological results of: lipids, liver and renal functions, blood cell count, HbA1c, CRP , Blood chemistry and Blood and urine urea

    Time frame: 2 years before and after randomization and dissemination of health-related messages

  4. Impact on medical costs

    Changes between groups: * in euros of patients healthcare costs, * in type of costs (consultation, hospitalisation, etc), * in euros of the intervention impact, * in QALY of cost-effectiveness

    Time frame: 2 years after randomization and dissemination of health-related messages

07

Study locations

1 of 1 sites recruiting
  • Biogroup laboratories
    Nantes, 44000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 36 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jun 2026 → Jul 2026 and primary completion Jun 2029 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 9, 2026
StartActual
Jul 15, 2026was Jun 2026
Primary completionEst.
Jul 15, 2029was Jun 2029
CompletionEst.
Jun 15, 2032
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
Biogroup laboratories is now Recruiting
Nov 13, 2026
Start date
Jun 2026→Jul 15, 2026 (actual)
Nov 13, 2026
Primary completion
Jun 2029→Jul 15, 2029
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    Biogroup laboratories is now Recruiting
    Start date Jun 2026→Jul 15, 2026 (now actual)
    Primary completion Jun 2029→Jul 15, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07634718
Collaborators
Hospices Civils de Lyon, University Hospital, Toulouse, University Hospital, Tours, Biogroup Laboratoire de biologie médicale, Santé publique France-InVS (Institut National de Veille sanitaire)
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jul 15, 2026
Primary completion
Jul 15, 2029 (estimated)
Completion
Jun 15, 2032 (estimated)
Last update
Nov 13, 2026

Study contacts

Samy Hadjadj, PU-PH
Contact
samy.hadjadj@univ-nantes.fr
+33244768545 ext. +33244768545
Sonia Brinet
Contact
sonia.brinet@chu-nantes.fr
+33253526126
Samy Hadjadj, MD
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion